.png){kind=icon}
.png){kind=icon}
Return
Incretin-based therapies and craving: a clinical signal pointing to reward reprogramming
.png){kind=icon}
PRE
AI
M
E
R
DOI：10.1016/j.numecd.2026.104818.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Incretin therapies may reduce craving beyond metabolic effects • Tirzepatide could be linked to cocaine craving loss and abstinence • The possible mechanism of action could be the modulation of mesolimbic reward pathways (GLP-1 axis) • The present finding may support emerging link between metabolism and addiction biology • Calls for trials of incretin drugs in substance use disorders
Journal
N
IF:
0
Papers:
307
Citations:
0
Organization
Cited Papers